DE602004026578D1 - Neue pharmazeutische verwendungen von staurosporin-derivaten - Google Patents

Neue pharmazeutische verwendungen von staurosporin-derivaten

Info

Publication number: DE602004026578D1
Authority: DE; Germany
Prior art keywords: warm; new pharmaceutical; pharmaceutical uses; derivatives; treatment
Prior art date: 2003-06-18
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE602004026578T

Other languages

English (en)

Inventor

Steven Coutre

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novartis AG

Original Assignee

Novartis AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-06-18

Filing date

2004-06-17

Publication date

2010-05-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33539193&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602004026578(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-06-17 Application filed by Novartis AG filed Critical Novartis AG

2010-05-27 Publication of DE602004026578D1 publication Critical patent/DE602004026578D1/de

2024-06-18 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Immunology (AREA)
Hematology (AREA)
Neurology (AREA)
Obesity (AREA)
Ophthalmology & Optometry (AREA)
Biomedical Technology (AREA)
Child & Adolescent Psychology (AREA)
Neurosurgery (AREA)
Otolaryngology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

DE602004026578T 2003-06-18 2004-06-17 Neue pharmazeutische verwendungen von staurosporin-derivaten Expired - Lifetime DE602004026578D1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US47957503P	2003-06-18	2003-06-18
PCT/EP2004/006562 WO2004112794A2 (en)	2003-06-18	2004-06-17	New pharmaceutical uses of staurosporine derivatives

Publications (1)

Publication Number	Publication Date
DE602004026578D1 true DE602004026578D1 (de)	2010-05-27

Family

ID=33539193

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE602004026578T Expired - Lifetime DE602004026578D1 (de)	2003-06-18	2004-06-17	Neue pharmazeutische verwendungen von staurosporin-derivaten

Country Status (24)

Country	Link
US (2)	US8575146B2 (de)
EP (1)	EP1638574B1 (de)
JP (2)	JP5057780B2 (de)
CN (2)	CN100457111C (de)
AT (1)	ATE464052T1 (de)
AU (1)	AU2004248909B2 (de)
BE (1)	BE2017C067I2 (de)
BR (1)	BRPI0411563B8 (de)
CA (2)	CA2785950A1 (de)
CY (2)	CY1110179T1 (de)
DE (1)	DE602004026578D1 (de)
DK (1)	DK1638574T3 (de)
ES (1)	ES2344700T3 (de)
FR (1)	FR17C1063I2 (de)
HK (1)	HK1095519A1 (de)
HU (1)	HUS000503I2 (de)
LU (1)	LUC00055I9 (de)
MX (1)	MXPA05013722A (de)
NL (1)	NL300917I2 (de)
PL (1)	PL1638574T3 (de)
PT (1)	PT1638574E (de)
SI (1)	SI1638574T1 (de)
TW (1)	TWI324604B (de)
WO (1)	WO2004112794A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI324604B (en) *	2003-06-18	2010-05-11	Novartis Ag	New use of staurosporine derivatives
US20060014165A1 (en) *	2003-07-14	2006-01-19	Decode Genetics Ehf.	Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association
CN101693031A (zh)	2003-11-18	2010-04-14	诺瓦提斯公司	Kit突变形式的抑制剂
WO2005115385A1 (en) *	2004-05-24	2005-12-08	Ab Science	Use of c-kit inhibitors for treating acne
US20090054358A1 (en) *	2004-07-19	2009-02-26	The John Hopkins University	Flt3 inhibitors for immune suppression
MX2007001155A (es) *	2004-07-29	2007-08-14	Creabilis Therapeutics Spa	Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
GB0419159D0 (en) *	2004-08-27	2004-09-29	Novartis Ag	Organic compounds
EP1879585B1 (de) *	2005-05-02	2013-04-17	Novartis AG	Verwendung von pyrimidylamimobenzamid-derivaten zur behandlung von systemischer mastozytose
KR101351682B1 (ko) *	2005-07-20	2014-01-14	피터 발렌트	전신 비만세포증 치료용 조성물
EP1951255A1 (de) *	2005-11-14	2008-08-06	Universität Zürich	Staurosporin-derivate zur verwendung bei alveolarem rhabdomyosarkom
WO2009092442A1 (en) *	2008-01-23	2009-07-30	Universidad De Barcelona	Treatment of portal hypertension and related conditions by combined inhibition of the vegf and pdgf signalling pathways
WO2012064981A2 (en)	2010-11-10	2012-05-18	National Jewish Health	Methods to test allergic conditions
US20210401859A1 (en)	2018-11-01	2021-12-30	Syros Pharmaceuticals, Inc.	Methods of treating cancer in biomarker-identified patients with non-covalent inhibitors of cyclin-dependent kinase 7 (cdk7)
US11325978B2 (en) *	2018-11-06	2022-05-10	The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services	Compositions and methods for treating beta-globinopathies
US11839619B2 (en) *	2019-09-16	2023-12-12	The Regents Of The University Of California	Methods for treatment of pediatric systemic mastocytosis

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4639455A (en) *	1984-10-02	1987-01-27	Key Pharmaceuticals, Inc.	Means of aiding in the prevention of sudden infant death syndrome
JPH0826037B2 (ja)	1987-01-22	1996-03-13	協和醗酵工業株式会社	生理活性物質ｋ−２５２の誘導体
US5093330A (en) *	1987-06-15	1992-03-03	Ciba-Geigy Corporation	Staurosporine derivatives substituted at methylamino nitrogen
CA2046801C (en) *	1990-08-07	2002-02-26	Peter D. Davis	Substituted pyrroles
DE69229490T2 (de)	1991-05-09	2000-02-17	Neurim Pharmaceuticals (1991) Ltd., Tel Aviv	Melatonin enthaltende Arzneimittel
AR004480A1 (es) *	1995-04-06	1998-12-16	Amico Derin C D	Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen
DK0912184T3 (da) *	1996-06-25	2002-11-25	Cephalon Inc	Anvendelse af K-252a-derivat til behandlingen af perifere eller centrale nervelidelser og cytokinoverproduktion
US6093740A (en) *	1997-04-30	2000-07-25	Eli Lilly And Company	Therapeutic treatment for skin disorders
WO1999062537A1 (en) *	1998-06-04	1999-12-09	The Rockefeller University	Methods and agents for modulating the immune response and inflammation involving monocyte and dendritic cell membrane proteins
GB9903547D0 (en) *	1999-02-16	1999-04-07	Novartis Ag	Organic compounds
ATE301661T1 (de) *	2000-12-08	2005-08-15	Ortho Mcneil Pharm Inc	Makroheterocyclische verbindungen als kinase inhibitoren
GB0108606D0 (en)	2001-04-05	2001-05-23	Novartis Ag	Organic compounds
WO2003002109A2 (en) *	2001-06-29	2003-01-09	Ab Science	Use of tyrosine kinase inhibitors for treating autoimmune diseases
US20030091974A1 (en) *	2001-06-29	2003-05-15	Alain Moussy	Method for screening compounds capable of depleting mast cells
NZ532136A (en) *	2001-10-30	2006-08-31	Novartis Ag	Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity
US6998391B2 (en)	2002-02-07	2006-02-14	Supergen.Inc.	Method for treating diseases associated with abnormal kinase activity
WO2004091663A1 (ja) *	2003-04-18	2004-10-28	Kyowa Hakko Kogyo Co., Ltd.	神経再生薬
US20070037882A1 (en) *	2003-04-22	2007-02-15	Astellas Pharma Inc.	Remedy for cerebral neurodegenerative diseases using ppar agonist
TWI324604B (en) *	2003-06-18	2010-05-11	Novartis Ag	New use of staurosporine derivatives
CN101693031A (zh)	2003-11-18	2010-04-14	诺瓦提斯公司	Kit突变形式的抑制剂

2004
- 2004-06-16 TW TW093117368A patent/TWI324604B/zh active
- 2004-06-17 AU AU2004248909A patent/AU2004248909B2/en not_active Expired
- 2004-06-17 DE DE602004026578T patent/DE602004026578D1/de not_active Expired - Lifetime
- 2004-06-17 ES ES04740016T patent/ES2344700T3/es not_active Expired - Lifetime
- 2004-06-17 SI SI200431450T patent/SI1638574T1/sl unknown
- 2004-06-17 CN CNB2004800168219A patent/CN100457111C/zh not_active Expired - Lifetime
- 2004-06-17 CA CA2785950A patent/CA2785950A1/en not_active Abandoned
- 2004-06-17 DK DK04740016.3T patent/DK1638574T3/da active
- 2004-06-17 CN CNA2007101658371A patent/CN101164539A/zh active Pending
- 2004-06-17 US US10/560,669 patent/US8575146B2/en active Active
- 2004-06-17 CA CA2527703A patent/CA2527703C/en not_active Expired - Lifetime
- 2004-06-17 BR BRPI0411563A patent/BRPI0411563B8/pt not_active Application Discontinuation
- 2004-06-17 JP JP2006515982A patent/JP5057780B2/ja not_active Expired - Lifetime
- 2004-06-17 AT AT04740016T patent/ATE464052T1/de active
- 2004-06-17 WO PCT/EP2004/006562 patent/WO2004112794A2/en active Application Filing
- 2004-06-17 EP EP04740016A patent/EP1638574B1/de not_active Expired - Lifetime
- 2004-06-17 MX MXPA05013722A patent/MXPA05013722A/es active IP Right Grant
- 2004-06-17 PT PT04740016T patent/PT1638574E/pt unknown
- 2004-06-17 PL PL04740016T patent/PL1638574T3/pl unknown
2007
- 2007-01-18 HK HK07100635.4A patent/HK1095519A1/xx not_active IP Right Cessation
2010
- 2010-07-06 CY CY20101100627T patent/CY1110179T1/el unknown
2012
- 2012-04-26 JP JP2012101493A patent/JP2012144572A/ja active Pending
2013
- 2013-06-27 US US13/929,438 patent/US20130289018A1/en not_active Abandoned
2017
- 2017-12-07 NL NL300917C patent/NL300917I2/nl unknown
- 2017-12-12 LU LU00055C patent/LUC00055I9/fr unknown
- 2017-12-14 HU HUS1700053C patent/HUS000503I2/hu unknown
- 2017-12-19 BE BE2017C067C patent/BE2017C067I2/fr unknown
- 2017-12-22 CY CY2017048C patent/CY2017048I2/el unknown
- 2017-12-28 FR FR17C1063C patent/FR17C1063I2/fr active Active

Also Published As

Publication number	Publication date
JP2012144572A (ja)	2012-08-02
CA2785950A1 (en)	2004-12-29
HUS000503I2 (hu)	2021-03-29
BRPI0411563A (pt)	2006-08-01
DK1638574T3 (da)	2010-08-02
TWI324604B (en)	2010-05-11
US20130289018A1 (en)	2013-10-31
NL300917I1 (nl)	2017-12-12
US20070299049A1 (en)	2007-12-27
FR17C1063I1 (de)	2018-02-16
PT1638574E (pt)	2010-07-14
JP5057780B2 (ja)	2012-10-24
AU2004248909B2 (en)	2008-05-08
NL300917I2 (nl)	2018-01-09
CY2017048I1 (el)	2018-09-05
TW200512213A (en)	2005-04-01
MXPA05013722A (es)	2006-03-08
BE2017C067I2 (de)	2023-08-09
JP2006527727A (ja)	2006-12-07
EP1638574A2 (de)	2006-03-29
LUC00055I2 (de)	2018-02-21
EP1638574B1 (de)	2010-04-14
HK1095519A1 (en)	2007-05-11
PL1638574T3 (pl)	2010-09-30
LUC00055I9 (de)	2022-11-09
CY2017048I2 (el)	2018-09-05
CN100457111C (zh)	2009-02-04
US8575146B2 (en)	2013-11-05
HUS1700053I1 (hu)	2018-01-29
WO2004112794A3 (en)	2005-06-16
BRPI0411563B8 (pt)	2021-05-25
BRPI0411563B1 (pt)	2019-09-24
CN1805749A (zh)	2006-07-19
AU2004248909A1 (en)	2004-12-29
CN101164539A (zh)	2008-04-23
WO2004112794A2 (en)	2004-12-29
ES2344700T3 (es)	2010-09-03
SI1638574T1 (sl)	2010-08-31
ATE464052T1 (de)	2010-04-15
LUC00055I1 (de)	2017-12-14
FR17C1063I2 (fr)	2019-05-03
CY1110179T1 (el)	2015-01-14
CA2527703C (en)	2012-10-23
CA2527703A1 (en)	2004-12-29

Publication	Publication Date	Title
HUS1700053I1 (hu)	2018-01-29	Staurosporin-származékok új gyógyászati alkalmazásai
DK1611088T3 (da)	2009-10-19	Hydroxymater som terapeutiske midler
ATE452129T1 (de)	2010-01-15	N-phenyl-2-pyrimidine-amine derivatives
ATE411022T1 (de)	2008-10-15	Pyridylpyrrol-derivate als wirksame kinase-hemmer
EA200970595A1 (ru)	2010-02-26	Производные замещенных индазолов, активные в качестве ингибиторов киназ
EA200971053A1 (ru)	2010-06-30	Способы лечения кожных язв
BRPI0410727A (pt)	2006-06-20	composto, composição farmacêutica, e, uso de um composto
ATE529417T1 (de)	2011-11-15	3',4',5-trimethoxyflavonderivate als die schleimsekretion stimulierendes mittel, entsprechendes verfahren und pharmazeutische zusammensetzung, die diese enthält
BR0313718A (pt)	2005-07-12	Composto, processo para a preparação do mesmo, composição farmacêutica, métodos para tratar um indivìduo humano ou animal sofrendo de uma condição que é mediada por cox-2 e para tratar um indivìduo humano ou animal sofrendo de um distúrbio inflamatório, e, uso de um composto
NO20055891L (no)	2006-02-07	Kinazolinderivater som aurorakinaseinhibitorer
EA200800075A1 (ru)	2008-04-28	Схема дозирования для празугреля
EA200401319A1 (ru)	2005-04-28	Новые гетероциклические соединения, способы их получения и фармацевтические композиции, содержащие эти соединения, и их использование в медицине
EA200500427A1 (ru)	2005-08-25	Способы лечения пациентов, страдающих синдромом усталых ног или связанными с ним заболеваниями
ATE412630T1 (de)	2008-11-15	C2-disubstituierte indan-1-ol-systeme und ihre verwendung als arzneimittel
BR0314647A (pt)	2005-08-02	Uso de derivados de 4-piridilmetil-ftalazina para a preparação de um medicamento para o tratamento de sìndromes melodisplásicas
RU2006126471A (ru)	2008-01-27	Способ лечения воспалительных заболеваний слюнных желез
TH401002069A (th)	2019-05-10	การใช้แบบใหม่ของอนุพันธ์สเทาโรสพอรีน
EA200701086A1 (ru)	2007-12-28	Производные изоксазола, их фармацевтические композиции и способ лечения невропатической боли
EA200900313A1 (ru)	2009-08-28	Производные бензо[1,2,3]тиадиазина

Legal Events

Date	Code	Title	Description
2018-02-14	R065	Request for grant of supplementary protection certificate validly filed	Free format text: PRODUCT NAME: MIDOSTAURIN ODER EIN SALZ DAVON; REGISTRATION NO/DATE: EU/1/17/1218 20170918 Spc suppl protection certif: 122018000016 Filing date: 20180118 Expiry date: 20240618 Extension date: 20290617
2019-04-30	R067	Examining division decision granting supplementary protection certificate	Free format text: PRODUCT NAME: MIDOSTAURIN ODER EIN SALZ DAVON; REGISTRATION NO/DATE: EU/1/17/1218 20170918 Spc suppl protection certif: 122018000016 Filing date: 20180118 Expiry date: 20240618 Extension date: 20290617
2019-06-07	R069	Supplementary protection certificate granted	Free format text: PRODUCT NAME: MIDOSTAURIN ODER EIN SALZ DAVON; REGISTRATION NO/DATE: EU/1/17/1218 20170918 Spc suppl protection certif: 122018000016 Filing date: 20180118 Expiry date: 20240618 Extension date: 20290617

Date

Code

Title

Description

2018-02-14

R065

Request for grant of supplementary protection certificate validly filed

Free format text: PRODUCT NAME: MIDOSTAURIN ODER EIN SALZ DAVON; REGISTRATION NO/DATE: EU/1/17/1218 20170918

Spc suppl protection certif: 122018000016

Filing date: 20180118

Expiry date: 20240618

Extension date: 20290617

2019-04-30

R067

Examining division decision granting supplementary protection certificate

Free format text: PRODUCT NAME: MIDOSTAURIN ODER EIN SALZ DAVON; REGISTRATION NO/DATE: EU/1/17/1218 20170918

Spc suppl protection certif: 122018000016

Filing date: 20180118

Expiry date: 20240618

Extension date: 20290617

2019-06-07

R069

Supplementary protection certificate granted

Free format text: PRODUCT NAME: MIDOSTAURIN ODER EIN SALZ DAVON; REGISTRATION NO/DATE: EU/1/17/1218 20170918

Spc suppl protection certif: 122018000016

Filing date: 20180118

Expiry date: 20240618

Extension date: 20290617

DE602004026578D1 - Neue pharmazeutische verwendungen von staurosporin-derivaten - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (2)

Publications (1)

Family

ID=33539193

Family Applications (1)

Country Status (24)

Families Citing this family (15)

Family Cites Families (20)

Also Published As

Similar Documents

Legal Events